877287-47-3Relevant academic research and scientific papers
Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase
Gentles, Robert G.,Ding, Min,Bender, John A.,Bergstrom, Carl P.,Grant-Young, Katharine,Hewawasam, Piyasena,Hudyma, Thomas,Martin, Scott,Nickel, Andrew,Regueiro-Ren, Alicia,Tu, Yong,Yang, Zhong,Yeung, Kap-Sun,Zheng, Xiaofan,Chao, Sam,Sun, Jung-Hui,Beno, Brett R.,Camac, Daniel M.,Chang, Chong-Hwan,Gao, Mian,Morin, Paul E.,Sheriff, Steven,Tredup, Jeff,Wan, John,Witmer, Mark R.,Xie, Dianlin,Hanumegowda, Umesh,Knipe, Jay,Mosure, Kathy,Santone, Kenneth S.,Parker, Dawn D.,Zhuo, Xiaoliang,Lemm, Julie,Liu, Mengping,Pelosi, Lenore,Rigat, Karen,Voss, Stacey,Wang, Yi,Wang, Ying-Kai,Colonno, Richard J.,Gao, Min,Roberts, Susan B.,Gao, Qi,Ng, Alicia,Meanwell, Nicholas A,Kadow, John F.
, p. 1855 - 1879 (2014/04/03)
Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors. Subsequent iterations of analogue design and synthe
